Investment Opportunity

Showing 2091 articles
Business

AbCellera Biologics: A Tale of Two Valuations Amid Steep Share Decline

Shares of antibody discovery firm AbCellera Biologics plunged 16.8% last week, reigniting debate over its true worth. While a discounted cash flow model suggests deep undervaluation, its sky-high price-to-sales ratio paints a starkly different picture, leaving investors to navigate conflicting signals in a volatile biotech market.

Business

ManpowerGroup Sees 'Stabilization' in Q4 as Demand Firms, Cost Cuts Take Hold

ManpowerGroup reported a return to modest organic growth in its fourth quarter, with executives citing improving demand and the benefits of ongoing cost optimization. While stopping short of declaring a broad recovery, the staffing giant highlighted sequential improvements in key markets and pointed to AI-driven productivity tools as a key differentiator.